

### REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

Initially, Applicants and their undersigned representative wish to express their appreciation of the Examiner for the several informal telephone conferences held regarding the scope of the claims. Based upon the last telephone conference, the Examiner has kindly agreed to examine tricyclic compounds and fused compounds including but not limited to tetracyclic rings.

The claims have been amended so as to be directed to the elected invention and so as to address and overcome each informality and ground of objection noted by the Examiner in the Official Action. It should be noted that claims 21-27 correspond to former claims 11-15 and 19-20, respectively. It should be noted that new claim 25 includes new compounds which were originally recited in claim 15. The new compounds are tricyclic 1,3-oxazine compounds which are examples 474, 493, 512, 531, 533, 534, 541, 542, 689, 690 and 539 of the specification.

It should further be noted that new claim 28 has been added for additional patent protection and is supported in the specification for example on page 182, lines 17-18.

Favorable action on the merits is solicited.

Respectfully submitted,

Takashi HAYAMA et al.

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

By: Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/kes  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
October 8, 2004